Welcome to our dedicated page for IONIS PHARMACEUTICALS SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IONIS PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IONIS PHARMACEUTICALS's regulatory disclosures and financial reporting.
Ionis Pharmaceuticals EVP Research Eric Swayze reported equity award activity and related stock sales. On January 15, 2026, restricted stock units vested, resulting in the acquisition of 21,366 shares of common stock at $0.0 per share, after which he held 51,819 shares directly. On January 16, 2026, he sold 9,884 shares of common stock at a weighted average price of $75.34 in an automatic sale to cover tax withholding, leaving 41,935 shares held directly. An account for his son held 318 shares after a sale of 49 shares.
He received a grant of 25,800 performance restricted stock units, representing the maximum earnable based on a three-year total shareholder return performance period, and 9,675 additional restricted stock units. His son was granted 225 restricted stock units. Each unit represents a contingent right to one share of Ionis common stock or its cash value, generally vesting in four equal annual installments.
Ionis Pharmaceuticals executive Eugene Schneider, EVP and Chief Clinical Development Officer, reported a mix of stock grants, vesting, and a sale. On 01/15/2026, 21,685 restricted stock units vested and were converted into common shares at an exercise price of $0.0, increasing his directly held common stock to 73,192 shares.
On the same date, he received a grant of 25,800 Performance Restricted Stock Units (PRSUs), representing the maximum 200% of target that may be earned after a three-year performance period based on relative total shareholder return, and a separate grant of 9,675 time-based RSUs that vest in four equal annual installments. On 01/16/2026, 9,302 common shares were sold at a weighted average price of $75.59 in an automatic sale to cover tax withholding obligations under the company’s equity plan, leaving him with 63,890 common shares directly owned, along with derivative holdings of PRSUs and RSUs.
Ionis Pharmaceuticals executive Patrick R. O'Neil, EVP, CLO & General Counsel, reported several equity transactions in Ionis common stock and equity awards.
On 01/15/2026, 21,473 shares of common stock were acquired at $0.0 upon vesting and release of Restricted Stock Units, increasing his directly held common stock to 75,362 shares. The same day, derivative positions changed as 25,800 Performance Restricted Stock Units were granted at $0.0, representing the maximum that may be earned after a three-year performance period tied to relative total shareholder return, and 9,675 additional Restricted Stock Units were granted.
On 01/16/2026, O'Neil sold 9,191 shares of common stock at a weighted average price of $75.84 in an automatic sale to cover tax withholding obligations under the company’s equity plan, leaving 66,171 common shares directly owned.
Ionis Pharmaceuticals Chief Executive Officer and director Brett P. Monia reported multiple equity award transactions and a related share sale. On January 15, 2026, 89,145 shares of common stock were acquired at $0.0 per share through the vesting and release of previously granted restricted stock units, increasing his directly held common stock to 268,717 shares. On the same day, he received 113,880 Performance Restricted Stock Units (PRSUs), representing the maximum earnable amount based on a three-year performance period, and 42,705 additional restricted stock units under the company’s equity incentive plan.
On January 16, 2026, Monia sold 44,034 common shares at a weighted average price of $74.82 per share in an automatic sale to cover required tax withholding obligations tied to the RSU vesting. Following these transactions, he directly beneficially owned 224,683 shares of common stock, alongside substantial outstanding PRSU and RSU awards that may convert into shares or cash in the future based on vesting and performance conditions.
Ionis Pharmaceuticals executive Holly Kordasiewicz reported a stock option grant under the company’s equity incentive plan. On 01/02/2026, she received a non-qualified stock option to purchase 7,500 shares of Ionis Pharmaceuticals common stock at an exercise price of $79.67 per share.
According to the filing, none of these options were exercisable on the grant date. 25% of the option shares will vest and become exercisable on 01/02/2027, with the remaining shares vesting in 36 equal monthly installments over the following three years, so full vesting occurs over four years. After this grant, Kordasiewicz beneficially owned 16,600 stock options in total, held directly.
Ionis Pharmaceuticals executive Holly B. Kordasiewicz, EVP and Chief Development Officer, reported multiple equity transactions. On 01/15/2026, 11,119 shares of common stock were acquired at $0.0 per share through the vesting and release of previously granted restricted stock units. On 01/16/2026, 4,141 shares were sold at a weighted average price of $75.66 per share in an automatic sale to cover tax withholding obligations under the company’s equity incentive plan, leaving 14,718 common shares directly owned.
On the derivative side, restricted stock units were exercised or granted at $0.0 per unit on 01/15/2026. An RSU conversion of 11,119 units reduced the RSU balance to 20,830 units. Additional grants of 13,650 and 11,250 RSUs increased the total RSU holdings to 45,730 units. Each RSU represents the right to receive one share of Ionis common stock or its cash equivalent, vesting in four equal annual installments.
Ionis Pharmaceuticals executive Kyle Jenne reported equity award activity and a small stock sale. On January 15, 2026, Jenne acquired 7,013 shares of common stock at $0.00 through the vesting and release of previously granted restricted stock units. The filing shows he then held 18,212 common shares directly.
On the same date, he received 25,800 performance restricted stock units, representing the maximum that may be earned over a three-year period based on Ionis’s relative total shareholder return, and 9,675 time-based restricted stock units that vest in four equal annual installments. On January 16, 2026, Jenne sold 1,823 shares of common stock at a weighted average price of $75.96, in an automatic sale to cover tax-withholding obligations, leaving him with 16,389 common shares held directly.
Ionis Pharmaceuticals EVP, Finance & CFO Elizabeth L. Hougen reported several equity award transactions and a small share sale. On January 15, 2026, 28,729 Restricted Stock Units (RSUs) vested and were converted into common stock at an exercise price of $0.0, and she received a new grant of 34,360 Performance RSUs and 12,885 RSUs under the company’s 2011 Equity Incentive Plan. The performance units may vest after a three-year period based on relative total shareholder return, with the amount reported representing the maximum that can be earned.
On January 16, 2026, she sold 12,922 shares of common stock at a weighted average price of $75.22 to cover tax withholding obligations related to the RSU vesting. After these transactions, she directly held 126,307 shares of common stock, 120,995 Performance RSUs, and 68,825 RSUs.
Ionis Pharmaceuticals executive Shannon L. Devers, EVP and Chief Human Resources Officer, reported multiple equity transactions in January 2026. On January 15, 2026, 17,377 shares of common stock were acquired upon vesting of restricted stock units at an exercise price of $0.0, and on January 16, 2026, 8,353 shares of common stock were sold in an automatic sale to cover tax withholding at a weighted average price of $75.95.
Devers also received 25,800 Performance Restricted Stock Units, representing the maximum that may be earned based on a three-year performance period, and 9,675 Restricted Stock Units that vest in four equal annual installments. Following these transactions, she directly beneficially owned 26,518 shares of common stock, 47,800 Performance RSUs, and 52,704 RSUs, each RSU representing a contingent right to one share of Ionis common stock or its cash equivalent.
Ionis Pharmaceuticals executive Brian Birchler reported several equity transactions. On January 15, 2026, 20,089 shares of common stock were acquired at $0.0 per share upon vesting and release of restricted stock units, increasing his direct holdings to 68,915 shares. On January 16, 2026, he sold 8,480 shares of common stock at a weighted average price of $75.11 per share in an automatic sale to cover tax withholding, leaving 60,435 common shares directly owned.
Birchler also received equity awards on January 15, 2026, including 25,800 Performance Restricted Stock Units (PRSUs), representing the maximum that may be earned based on three‑year relative total shareholder return, and a grant of 9,675 Restricted Stock Units (RSUs). These PRSUs may vest at the end of the three‑year period, while RSUs generally vest in four equal annual installments, each unit representing a right to one share of Ionis common stock or its cash equivalent.